Banner Health

Banner Health, doing business as Banner Research Institute, is a Phoenix, Arizona-based non-profit healthcare system and tax-exempt corporate entity that operates as a federal research grant recipient and contract performer, with 54% of recent awards in the sub-awardee role under prime academic and research institutions. Banner Health competes primarily in full-and-open federal research and medical education procurements without set-aside designations, spanning 113 recent awards across neurodegenerative disease research, clinical biomarker development, medical education, and laboratory testing services for federal health agencies.

Banner Health's federal footprint centers overwhelmingly on the National Institute on Aging (NIA), which accounts for 58 awards (51% of recent award count) with $7.3 million in combined potential value — a high-volume, low-dollar-magnitude pattern driven by transactional purchase orders for human brain tissue, laboratory supplies, and biospecimen services supporting Alzheimer's disease and related dementias research. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 (VISN 22) anchors the potential-value ranking with 10 awards carrying $58.9 million combined potential value, dominated by a single $41.9 million indefinite delivery contract (VA25816D0008) for graduate medical education support and related healthcare services running through 2030. These two customer agencies represent 92% of Banner Health's recent combined potential value, though they operate in distinct capability spaces: NIA research partnerships versus VA medical education and healthcare delivery.

As a prime research institution, Banner Health holds federal grant awards from the National Institute on Aging for Alzheimer's disease prevention and biomarker research. A $6.996 million firm-fixed-price purchase order awarded August 1, 2026, for NULISA proteomic liquid biopsy testing services to identify Alzheimer's disease and related dementias biomarkers (running through July 31, 2029, with performance in North Bethesda, Maryland) exemplifies Banner's validated laboratory capability — the procurement was sole-sourced under 41 U.S.C. 3304(a)(1) because Banner maintains a biobanked NULISA quality control cohort and longitudinal analytical infrastructure that no alternate vendor could replicate without unacceptable delay. Banner also holds project grants from NIA for the Alzheimer's Prevention Initiative ADAD Colombia Trial Program (awarded September 1, 2024, running through August 31, 2029), tracer harmonization research for amyloid and tau PET imaging using statistical and deep learning techniques (awarded August 1, 2022, with completion extending to July 31, 2027), and Lewy body dementia biomarker seeding assay research (awarded September 15, 2021, completing August 31, 2026). Additional representative prime awards include a $538 thousand VA definitive contract for graduate medical education base year support (awarded October 20, 2025, running through June 30, 2030) and multiple NIA purchase orders for brain tissue specimens, ex vivo hippocampus mapping materials, and cerebellar cortex samples ranging from $23 thousand to $61 thousand supporting neuropathology research infrastructure.

In its sub-awardee role, Banner Health provides frozen human brain tissue specimens, neuropathological expertise, and clinical consultation to academic prime grantees across multiple NIH-funded programs. Sub-awards from the University of California Irvine, the University of California San Diego, Stanford University, the University of Washington (National Alzheimer's Coordinating Center), the University of Wisconsin System, Boston University, Indiana University, and the University of Arizona position Banner as a critical biospecimen source and research infrastructure provider. Banner's Brain and Body Donation Program (BBDP), directed by neuropathologist Thomas Beach since 1997, supplies characterized human brain tissue from cognitively normal, mildly impaired, and Alzheimer's disease dementia donors, as well as rapid-autopsy specimens from subjects with Parkinson's disease, Lewy body dementia, and other neurodegenerative conditions. Representative sub-awards include tissue provision and co-investigator support to UC San Diego for joint estimation diffusion imaging of aging and Alzheimer's disease (awarded October 26, 2023, with modifications through 2025), neuropathologically characterized brain specimens and consultation to UCLA for single-nucleus sequencing and synaptic marker quantification (awarded May 27, 2025), and rapid-autopsy pneumonia and COVID-19 lung specimens plus cardiac serum samples to Boston University for respiratory pathogen serologic and transcriptomic studies (awarded July 17, 2024, and April 25, 2022). Banner's sub-award footprint also includes Geidy Serrano leading enrollment and diagnostic phenotyping work on early-onset Alzheimer's disease studies as a site PI under Trustees of Indiana University (awards through August 14, 2024) and Eric Reiman serving as co-principal investigator and imaging lead on the DIAGNOSE CTE consortium under Boston University (awarded November 13, 2024).

Award activity has grown from ten awards in 2022 to twenty-four in 2024, though declining to fourteen in 2025 and eight in 2026 to date — a trajectory shaped by NIA's transactional testing and supply orders continuing at steady volume while VA contract obligations have matured and recompete exposure is minimal (only five awards totaling $30 thousand reach ultimate completion inside the next twenty-four months). Banner Health's named subsidiaries include Banner-University Medical Group, Banner-University Physician Specialists, and Banner Imaging Services Colorado, among 49 total subsidiary entities, reflecting the parent's multi-state healthcare delivery network spanning Arizona, Colorado, Wyoming, and other markets; subsidiary structure does not materially differentiate the federal award footprint, which operates under Banner Health's unified federal identity.

Banner Health's primary NAICS representation spans General Medical and Surgical Hospitals (11 awards), Colleges, Universities, and Professional Schools (9 awards), Biological Product Manufacturing (3 awards), Blood and Organ Banks (3 awards), and Testing Laboratories and Services (2 awards), with PSC concentration in Medical-Surgery, Drugs and Biologicals, Laboratory Equipment and Supplies, Medical-Managed Healthcare, and Reference Laboratory Testing. The vendor competes as a large non-profit healthcare research organization without small business set-asides, positioning its federal strategy around unique institutional assets — neuropathological expertise, longitudinal biobanks, clinical trial infrastructure, and rapid-autopsy networks — that support federal health research and VA medical education missions rather than commercially commoditized services.